SARS-CoV-2 variants,immune escape,COVID-19 vaccine,and therapeutic strategies  

作　　者：Haiying Que Li Chen Xiawei Wei 

机构地区：[1]Laboratory of Aging Research and Cancer Drug Target,State Key Laboratory of Biotherapy and Cancer Center,National Clinical Research Center for Geriatrics,West China Hospital,Sichuan University,Chengdu 610041,China

出　　处：《Science China(Life Sciences)》2023年第2期406-410,共5页中国科学（生命科学英文版）

基　　金：supported by the National Science Foundation for Excellent Young Scholars(32122052);the National Natural Science Foundation Regional Innovation and Development(U19A2003)。

摘　　要：The global pandemic of coronavirus disease 2019(COVID-19) caused by severe acute respiratory syndrome coronavirus2(SARS-CoV-2) has brought considerable challenges to worldwide public health and the economy. Over 535 million confirmed cases and 6.3 million deaths of COVID-19 were reported as of June 17, 2022(https://covid19.who.int/).

关 键 词：ACUTE RESPIRATORY VACCINE 

分 类 号：R563.1[医药卫生—呼吸系统]